Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?
Menendez
Javier A
JA
Department of Medicine, Breast Cancer Translational Research Program, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, Illinois 60201, USA. jmenendez@enh.org
Vellon
Luciano
L
Lupu
Ruth
R
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D002453:Cell Cycle / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D064429:Fatty Acid Synthases / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects*; D018734:Genes, erbB-2 / Q000502:physiology*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D000077403:Orlistat; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism
D019440:Anti-Obesity Agents; D000970:Antineoplastic Agents; D004247:DNA; D004791:Enzyme Inhibitors; D064429:Fatty Acid Synthases; D007783:Lactones; D000077403:Orlistat; D018719:Erb-b2 Receptor Tyrosine Kinases